Rallybio Corp RLYB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EDT
10.67UNCH (UNCH)
Volume
1,164
Close
10.67quote price arrow down-0.06 (-0.56%)
Volume
15,758
52 week range
5.90 - 21.00
Loading...
  • Open10.75
  • Day High10.84
  • Day Low10.53
  • Prev Close10.73
  • 52 Week High21.00
  • 52 Week High Date11/10/21
  • 52 Week Low5.90
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap342.83M
  • Shares Out32.13M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change11.84

KEY STATS

  • Open10.75
  • Day High10.84
  • Day Low10.53
  • Prev Close10.73
  • 52 Week High21.00
  • 52 Week High Date11/10/21
  • 52 Week Low5.90
  • 52 Week Low Date06/14/22
  • Market Cap342.83M
  • Shares Out32.13M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change11.84

RATIOS/PROFITABILITY

  • EPS (TTM)-1.84
  • P/E (TTM)-5.81
  • Fwd P/E (NTM)-4.57
  • EBITDA (TTM)-54.08M
  • ROE (TTM)-41.99%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Rallybio Corp

There is no recent news for this security.

Content From Our Affiliates

Profile

MORE
Rallybio Corporation is a clinical-stage biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering therapies that improve the lives of patients suffering from severe and rare diseases. It offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. It provides RLYB211, a polyclonal anti-HPA-1a antibody. Its RLYB211 is in Phase I/II clinical...
Martin Mackay Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Stephen Uden M.D.
President, Co-Founder, Chief Operating Officer, Chief Scientific Officer
Address
234 CHURCH STREET, SUITE 1020
New Haven, CT
06510
United States

Top Peers

SYMBOLLASTCHG%CHG
CBAY
Cymabay Therapeutics Inc
3.74-0.42-10.10%
NAUT
Nautilus Biotechnology Inc
2.94+0.10+3.52%
HUMA
Humacyte Inc
4.40+0.91+26.07%
TCRT
Alaunos Therapeutics Inc
1.78-0.08-4.30%
BMEA
Biomea Fusion Inc
11.50-0.42-3.52%